An investigational drug called apitegromab—a selective myostatin activation inhibitor—successfully preserved lean muscle mass when combined with tirzepatide in a phase II randomized trial, offering a potential solution to muscle loss associated with weight-loss medications.
The study, published in Nature Medicine, addresses an emerging concern among users of GLP-1 drugs like tirzepatide. As these medications gain widespread use for weight loss and diabetes management, clinicians and patients have observed unwanted loss of muscle alongside fat, sometimes colloquially termed “Ozempic butt.” The trial results suggest apitegromab could help mitigate this side effect when combined with tirzepatide, though the drug remains investigational and awaits FDA review.
The growing use of GLP-1 medications continues to drive research across multiple related areas. In a randomized trial presented at the American Diabetes Association annual meeting, Chinese adults with obesity lost 15.15% more weight with the dual GLP-1/glucagon agonist mazdutide compared with placebo. Meanwhile, an analysis published in JAMA found that Medicare’s $35 insulin cap decreased and stabilized out-of-pocket costs, increasing medication use among people with previously high expenses. Separately, research published in the American Journal of Public Health found that swapping animal protein for plant protein was associated with decreased body weight in postmenopausal women, independent of total calorie changes.
Beyond pharmaceutical interventions, qualitative research emphasizes the importance of behavioral support alongside medication. A study in JAMA Network Open found that patients described GLP-1 therapy as a facilitator rather than a replacement for lifestyle change, underscoring the need for concurrent behavioral interventions to sustain treatment benefits. Additionally, a randomized trial found that semaglutide appeared to slow epigenetic aging in people with HIV-associated lipohypertrophy, suggesting potential broader health benefits beyond weight and glucose control.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.medpagetoday.com/endocrinology/generalendocrinology/121675